A New Paradigm in the Understanding and Treatment of the Metabolic Syndrome: Targeting Alterations within the Biological Clock System

Abbreviations for Figure 3:

1. CRH: Corticotropin Releasing Hormone
2. eNOS: Endothelial Nitric Oxide Synthase
3. FFA: Free Fatty Acids4. NPY: Neuropeptide Y
5. PVN: Paraventricular Nucleus
6. SCN: Suprachiasmatic Nucleus
7. SNS: Sympathetic Nervous System
8. TG: Triglycerides
9. VMH: Ventromedial Hypothalamus

References for Figure 3:

1. Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000;71:68-78.

2. Boundy VA, Cincotta AH. Hypothalamic adrenergic receptor changes in the metabolic syndrome of genetically obese (ob/ob) mice. Am J Physiol Regul Integr Comp Physiol. 2000; 279:R505-14.

3. Cincotta AH, Luo S, Liang Y. Hyperinsulinemia increases norepinephrine metabolism in the ventromedial hypothalamus of rats. Neuroreport. 2000;11:383-7.

4. Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol. 2000;278:R435-44.

5. Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol. 1993;264:E285-93.

6. Cincotta AH, Meier AH. Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus). J Endocrinol. 1985;106:173-6.

7. Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism. 1995;44:1349-55.

8. Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia,insulin resistance, and impaired glucose tolerance in the Syrian hamster,Mesocricetus auratus. Metabolism. 1991;40:639-44.

9. Davis LM, Pei Z, Trush MA, et al. Bromocriptine reduces steatosis in obese rodent models. J Hepatol. 2006;45:439-44.

10. Dicostanzo CA, Dardevet DP, Neal DW, et al. Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal. Am J Physiol Endocrinol Metab. 2006;290:E9-16.

11. Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Weighted Effects of Bromocriptine Treatment on Glucose Homeostasis during Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer. J Diabetes Metab. 2012;S2:007.

12. Ezrokhi M, Trubitsyna Y, Luo S, Cincotta AH. Timed Dopamine Agonist Treatment Ameliorates Both Vascular Nitrosative/Oxidative Stress Pathology and Aortic Stiffness in Arteriosclerotic, Hypertensive SHR Rats. Diabetes. 2010; 59(suppl1):A67.

13. Jetton TL, Liang Y, Cincotta AH. Systemic treatment with sympatholytic dopamine agonists improves aberrant beta-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice. Metabolism. 2001;50:1377-84.

14. Kraszewski KZ, Cincotta AH. Increased responsiveness of ventromedial hypothalamic neurons to norepinephrine in obese versus lean mice: relation to the metabolic syndrome. Int J Mol Med. 2000;5:349-55.

15. Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126:159-72.

16. Liang Y, Cincotta AH. Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice. Int J Obes Relat Metab Disord. 2001;25:698-704.

17. Liang Y, Jetton TL, Lubkin M, et al. Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci. 1998;54:703-11.

18. Liang Y, Lubkin M, Sheng H, et al. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta. 1998;1405:1-13.

19. Liang Y, Luo S, Cincotta AH. Long-term infusion of norepinephrine plus serotonin into the ventromedial hypothalamus impairs pancreatic islet function. Metabolism. 1999;48:1287-9.

20. Luo S, Ezrokhi M, Cincotta AH. Timed Daily Bromocriptine Administration Ameliorates Metabolic Syndrome and Normalizes Elevated Ventromedial Hypothalamic Catecholamines of Spontaneously Hypertensive Rats. Diabetes. 2008;57(suppl1):A627.

21. Luo S, Ezrokhi M, Trubitsyna Y, Cincotta AH. Intrahypothalamic circuitry regulating hypothalamic fuel sensing to induce insulin sensitivity or insulin resistance. Diabetologia. 2008;51:(Suppl1):S59.

22. Luo S, Ezrokhi M, Trubitsyna Y, Cincotta AH. Elevation of Serotonin Activity within the Ventromedial Hypothalamus (VMH) Induces the Hypertensive Insulin Resistant State in Rats Diabetes. 2011;60(Suppl1):A128.

23. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology. 1999;69:160-6.

24. Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology. 1999;70:460-5.

25. Luo S, Luo J, Cincotta AH. Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. Neuroreport. 1999;10:2073-7.

26. Luo S, Luo J, Meier AH, Cincotta AH. Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport. 1997;8:3495-9.

27. Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology. 1998;68:1-10.

28. Zhang Y, Luo S, Ezrokhi M, et al. Identification of a novel hypothalamic circuit regulating energy balance: dopaminergic projection from Supramammillary Nucleus (SuM) to Suprachiasmatic Nucleus (SCN) Diabetes. 2013;62(Suppl1):A525.